Nichi-Iko Sanofi-Aventis JV To Develop Biosimilars Within Five Years
This article was originally published in PharmAsia News
Executive Summary
Nichi-Iko president Yuichi Tamura said the company plans to develop and commercialize biosimilar products in Japan within five years through a joint venture with Sanofi-Aventis